Keyword: David Ricks

Eli Lilly's $1.1 billion Dermira bid is smart, some analysts say, because it brings in both a marketed drug and a phase 3 atopic dermatitis asset.

After senators criticized Eli Lilly on insulin affordability this week, CEO David Ricks called their report “nonsense." But now he's changed his tune.

A report from two senators concluded Eli Lilly's insulin generic has failed patients, but Lilly CEO David Ricks called that idea "nonsense."

Big Pharma CEOs have their own way of cozying up to the world’s second largest pharmaceutical market—by getting themselves Chinese names.

Lilly CEO David Ricks, in his second year on the job, hauled in a pay package larger than those of a few of his big pharma peers.

The move comes as Lilly and the other two big diabetes drugmakers face increasing political pressure on rising insulin prices.

Sweep out drug rebates for patient discounts instead? Supply chain players hate the idea, but Big Pharma CEOs are all over it.

Eli Lilly is the first pharma to add pricing information to its DTC TV advertising in a commercial for Trulicity this week, with more on the way.

Big biopharma CEOs gave most or all their campaign contributions to Republicans this season, but one went full blue with his $120,000.